Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/α-fetoprotein (AFP) levels
Shenghui Qin(Bayer (United States)), Ann‐Lii Cheng(National Taiwan University), Won Young Tak(Kyungpook National University Hospital), Shaoqing Yu(Intelligent Health (United Kingdom)), K. Burock(Bayer (United States)), D. Voliotis(Bayer (United States)), J. Kim(Bayer (United States)), J. Zou(Bayer (United States)), Tsai‐Hsiu Yang(Bayer (United States)), Chung‐Kan Tsao(Bayer (United States))
Cited by 1
Related Papers
Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Involvement of NF-κB-Jmjd3 Signaling
|Cellular Physiology and Biochemistry|2017|5.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k